Treats myasthenia gravis. Sold as Mestinon, Regonol, Pyridostigmine Bromide. Every FDA application for this active ingredient: 7 branded and 14 generic.
As of Nov 16, 2026, FDA lists 21 applications for Pyridostigmine Bromide (sold as Mestinon, Regonol, Pyridostigmine Bromide), first approved Apr 6, 1955, with 0 new uses approved and 0 published complete response letters.
| Pyridostigmine Bromide | Part D | $25.6M | +19% | 68,237 |
| Mestinon | Part D | $8.6M | +11% | 477 |
| Pyridostigmine Bromide ER | Part D | $6.9M | -21% | 4,119 |
| Regonol | Part D | $74K | +65% | 0 |
| Sugammadex-Induced Clenching During Neuromuscular Blockade ReversalNeuromuscular Blockade Reversal Agent, Perioperative Complications · Wonkwang University Hospital | Not applicable | Recruiting | May 8, 2025 |
| Telitacicept and Low-dose Steroids in Refractory Myasthenia GravisMyasthenia Gravis, Autoimmune Diseases · First Affiliated Hospital of Wenzhou Medical University | Phase 4 | Not yet recruiting | Dec 9, 2024 |
| LIFT: Life Improvement TrialME/CFS, Long COVID · Brigham and Women's Hospital | Phase 2 | Recruiting | Apr 16, 2024 |
| Pyridostigmine for the Treatment of Constipation in Parkinson DiseaseParkinson Disease, Constipation · University of Vermont Medical Center | Phase 2 | Recruiting | Nov 3, 2022 |
| Pyridostigmine Efficacy and Safety for Treatment of Ileus After Colorectal SurgeryPostoperative Ileus · Stefan Holubar MD MS FACS, FASCRS | Phase 2 / Phase 3 | Recruiting | Apr 19, 2022 |
| TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world StudyOcular Myasthenia Gravis · Tang-Du Hospital | — | Recruiting | Dec 2, 2019 |
| Vagal Stimulation in POTSPostural Tachycardia Syndrome · Vanderbilt University Medical Center | Phase 1 | Active, not recruiting | Apr 21, 2017 |
| Droxidopa / Pyridostigmine in Orthostatic HypotensionOrthostatic Hypotension · Mayo Clinic | Phase 2 | Enrolling by invitation | Jun 10, 2011 |
| Apr 6, 1955 | MestinonNDA 9829 · New molecular entity | Bausch | 11 | Marketed |
| Oct 2, 1955 | MestinonNDA 9830 · New dosage form | Bausch | 9 | Marketed |
| Jan 12, 1959 | MestinonNDA 11665 · New dosage form | Bausch | 13 | Marketed |
| Jan 25, 1965 | MestinonNDA 15193 · New dosage form | Bausch | 11 | Marketed |
| Aug 14, 1973 | RegonolNDA 17398 · New formulation or manufacturer | Sandoz | 18 | Marketed |
| Nov 27, 1990 | Pyridostigmine BromideANDA 89572 | Solvay | 0 | Discontinued |
| Dec 26, 2002 | Pyridostigmine BromideANDA 40457 | Impax Labs Inc | 0 | Discontinued |
| Feb 5, 2003 | Pyridostigmine BromideNDA 20414 · New dosage form | US Army | 5 | Discontinued |
| Apr 24, 2003 | Pyridostigmine BromideANDA 40502 | Impax Labs | 1 | Marketed |
| Oct 8, 2003 | Pyridostigmine BromideANDA 40512 | Ani Pharms | 1 | Marketed |
| Jun 22, 2015 | Pyridostigmine BromideANDA 205650 | Zydus Pharms | 0 | Marketed |
| Jun 26, 2015 | Pyridostigmine BromideANDA 204737 | Alvogen | 0 | Marketed |
| Sep 15, 2015 | Pyridostigmine BromideANDA 203184 | Impax Labs Inc | 0 | Discontinued |
| Aug 15, 2017 | Pyridostigmine BromideANDA 205464 | Rising | 0 | Marketed |
| Jul 20, 2018 | Pyridostigmine BromideANDA 211181 | Mlv | 0 | Marketed |
| Mar 8, 2019 | Pyridostigmine BromideANDA 211694 | Novitium Pharma | 0 | Marketed |
| Jan 9, 2020 | Pyridostigmine BromideANDA 208797 | Rising | 0 | Marketed |
| Jan 10, 2020 | Pyridostigmine BromideANDA 212702 | Amneal | 0 | Marketed |
| Apr 19, 2022 | Pyridostigmine BromideANDA 212405 | Milla Pharms | 0 | Marketed |
| Sep 21, 2023 | Pyridostigmine BromideANDA 216512 | Msn | 0 | Marketed |
| Oct 4, 2024 | Pyridostigmine BromideNDA 217604 · New formulation or manufacturer | Amneal | 1 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA